Pazopanib plus weekly paclitaxel versus weekly paclitaxel alone for platinum-resistant or platinum-refractory advanced ovarian cancer (MITO 11): a randomised, open-label, phase 2 trial
- 1 May 2015
- journal article
- research article
- Published by Elsevier in The Lancet Oncology
- Vol. 16 (5) , 561-568
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Incorporation of Pazopanib in Maintenance Therapy of Ovarian CancerJournal of Clinical Oncology, 2014
- Definitions for Response and Progression in Ovarian Cancer Clinical Trials Incorporating RECIST 1.1 and CA 125 Agreed by the Gynecological Cancer Intergroup (GCIG)International Journal of Gynecological Cancer, 2011
- A Phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancerGynecologic Oncology, 2010
- Weekly paclitaxel in the treatment of recurrent ovarian cancerNature Reviews Clinical Oncology, 2010
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- Phase II trial of weekly paclitaxel (80 mg/m2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: A Gynecologic Oncology Group studyGynecologic Oncology, 2006
- Evaluation of weekly low-dose paclitaxel and carboplatin treatment for patients with platinum-sensitive relapsed ovarian cancerGynecologic Oncology, 2005
- Phase II Trial of Weekly Single-Agent Paclitaxel in Platinum/Paclitaxel-Refractory Ovarian CancerJournal of Clinical Oncology, 2002
- Randomized Trial of Single Agent Paclitaxel Given Weekly Versus Every Three Weeks and with Peroral Versus Intravenous Steroid Premedication to Patients with Ovarian Cancer Previously Treated with PlatinumActa Oncologica, 2002
- Redefining the Target: Chemotherapeutics as AntiangiogenicsJournal of Clinical Oncology, 2001